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OBJECTIVE — To assess whether TCF7L2 polymorphism has a role in the deterioration of
glycemic control.
RESEARCH DESIGN AND METHODS — Metabolic variables were evaluated at base-
line and after 6-year follow-up in 1,480 Caucasian subjects from a population-based cohort.
RESULTS — At baseline, T-allele carriers showed signiﬁcantly lower BMI and homeostasis
modelassessmentfor-cellfunction(HOMA-B)valuesandhigherfastingglycemiaanddiabetes
prevalence. At follow-up, fasting glucose and HOMA-B index were increased and reduced,
respectively, in carriers of the T-allele. Incident impaired fasting glucose (IFG) and incident
diabeteswere5.7,10.7,16.9%and1.6,1.7,3.0%intheCC,CT,andTTgenotypes,respectively.
Inamultiplelogisticregressionmodel,theassociationbetweenincidentIFGandtheT-allelewas
signiﬁcant (odds ratio [OR] 2.08 [95% CI 1.35–3.20] and 3.56 [2.11–5.98] in CT and TT
genotypes, respectively).
CONCLUSIONS — The T-allele of TCF7L2 rs7903146 polymorphism was independently
associated with increasing fasting glucose values toward hyperglycemia in the follow-up.
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A
mong the variety of TCF7L2 poly-
morphisms correlating with type 2
diabetes, the single nucleotide
polymorphism (SNP) rs7903146 has
shown the strongest association with the
disease (1). We investigated the associa-
tion of the SNP rs7903146 with 1) type 2
diabetes or 2) impaired fasting glucose
(IFG) or 3) the metabolic syndrome (MS)
in an adult Italian population-based co-
hort both cross-sectionally and after
6-year follow-up.
RESEARCH DESIGN AND
METHODS— All 1,877 Caucasians
aged 45–64 years and representative of
the province of Asti (Italy) were invited to
participateinametabolicsurveyin2001–
2003; 1,658 (88.3%) agreed to partici-
pate by written informed consent. Both
participants and nonparticipants were
similar to the resident population of cor-
responding age with respect to sex com-
position, level of education, prevalence of
known diabetes, and living in a rural area
(2). Diabetes and MS were diagnosed ac-
cording to published recommendations
and criteria (3,4); the homeostasis model
assessment-insulin resistance (HOMA-
IR) index and the HOMA for -cell
(HOMA-B) function were calculated (5).
Genotyping for TCF7L2 SNP
rs7903146 utilized the real-time allele
discrimination method (Applied Biosys-
tems, Foster City, CA). All procedures
were in accordance with the Declaration
ofHelsinkiandapprovedbythelocaleth-
ics committee.
HOMA-IR,HOMA-B,insulin,andtri-
glyceride values were log-transformed
and used in all analyses. Multiple regres-
sionanalyses(forcontinuousvariables)or
multiple logistic regression analyses (for
dichotomic variables) were used to eval-
uate the associations between each vari-
able and the presence of the CT or TT
genotypes (introduced in the model as
dummy variables) after adjustments for
age, sex, familial diabetes, BMI, and waist
circumference. The capacity of the TT ge-
notype for predicting incident IFG and
diabetes was examined by calculating the
receiver operating characteristics (ROC)
curves and the area under the curve
(AUC).
RESULTS— From January to Novem-
ber 2008, patients were contacted for a
follow-up visit: 1,480/1,658 (89.3%)
were evaluated after excluding those who
died (n  61) and those whose blood
sampleswerenotavailableforgenotyping
(n  117). Mean follow-up was 6.1 
0.34 years. At baseline, 25.1% of patients
were on anti-hypertensive treatment and
4.7% were on hypoglycemic drugs.
Characteristics at baseline and fol-
low-up of subjects grouped by genotypes
are presented in Table 1. The rs7903146
genotypic distribution was in Hardy-
Weinberg equilibrium.
At baseline, carriers of the T-allele
showedsigniﬁcantlyhighervaluesoffast-
ing glucose and lower BMI and HOMA-B
index values in a regression model (Table
1). Prevalence of diabetes was signiﬁ-
cantly higher in subjects carrying the mi-
nor T-allele in a multiple logistic
regressionmodel,whilenosigniﬁcantdif-
ferences were detected for prevalence of
IFG and MS.
At follow-up, fasting glucose and
HOMA-B values were increased and re-
duced,respectively,inT-allelecarriers.In
these patients, prevalence of IFG, diabe-
tes, and MS were signiﬁcantly higher in a
multiplelogisticregressionmodelinboth
CT and TT genotypes (OR 1.78 [95% CI
1.06–2.99] and 3.10 [1.63–5.91] for di-
abetes; 1.81 [1.31–2.51] and [1.90–
4.39] for IFG; 1.34 [1.02–1.75] and 1.79
[1.22–2.64] for MS in CT and TT geno-
types, respectively). The association be-
tween T-allele and MS was exclusively
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cemia in these subjects.
Incident diabetes was almost double
in homozygous for the T-allele, but the
association was not signiﬁcant due to the
low case number. Incident IFG was two-
fold and threefold higher in the heterozy-
gous and homozygous T carriers,
respectively (OR 2.08 [95% CI 1.35–
3.20] and 3.56 [2.11–5.98] in CT and TT
genotypes, respectively). Adjustments for
smoking habits, lipid parameters, or
HOMA-B values did not signiﬁcantly af-
fect the results. The AUCs of the ROC
curves for the TT genotype were 0.56 for
incident IFG and 0.54 for incident
diabetes.
CONCLUSIONS — The major ﬁnd-
ings of the present study are: 1) a high
prevalence of the defective T-allele in an
Italian population-based cohort; 2) a sig-
niﬁcant association between the T-allele
and hyperglycemia and -cell dysfunc-
tionatbaselineandfollow-up;3)atwo-to
threefold higher risk of incident IFG in
the T-allele carriers at follow-up; and 4)
an increased prevalence of MS in the
T-allele carriers.
The minor T-allele is strongly associ-
ated with reduced HOMA-B levels, sug-
gesting that the polymorphism could
affect the ability of the -cells to secrete
insulin. These data indicate that SNP
rs7903146 polymorphism may modulate
thedegreeofinsulinsecretiontooffsetthe
prevailing level of insulin resistance with-
out being a cause of insulin resistance.
SNP rs7903146 acts like other TCF7L2
polymorphisms, such as rs12255372 (6).
The T-allele is signiﬁcantly associated
with lower BMI, so we can conﬁrm recent
studies that suggest that the variants do
nothaveaprimaryeffectonadiposity(7).
These studies showed that individuals
with the highest risk genotype and the
lowest birth weight had the greatest risk
of type 2 diabetes (8).
It has been reported that TCF7L2 ex-
erts its inﬂuence through an impairment
of insulin secretion. This impairment was
reportedly due to a functional defect in
the glucagon-like peptide-1 (GLP-1) sig-
naling in -cells and not due to defective/
failing GLP-1 secretion (9). It is unlikely
that the pathway of incretins by itself can
play a central role in the pathophysiology
of type 2 diabetes. We reported that
TCF7L2 may impact -cell function both
directly through modulating -cell re-
sponse to glucose and indirectly by mod-
ulating incretin action or secretion (10).
The prevalence of MS in subjects car-
rying the TT genotype was about twofold
higher at follow-up when compared with
theprevalenceatbaseline.Thisincrement
was almost exclusively due to the signiﬁ-
cantly higher prevalence of hyperglyce-
mia in this subgroup. The AUC values are
similar to those reported in literature
dealing with one single SNP (11).
Our study conﬁrms an effect of the
widely replicated TCF7L2 rs7903146
polymorphism on hyperglycemia in an
adult Italian population-based cohort
both in cross-sectional and longitudinal
evaluation. The independent association
ofTCF7L2polymorphismwithincreasing
fasting glucose values in the follow-up
may represent a marker for higher meta-
bolic risk, which is useful for developing
Table 1—Characteristics at baseline and follow-up by TCF7L2 rs7903146 genotypes
At baseline
CC CT P (95% CI) TT P (95% CI)
n 580 699 201
Frequency (%) 39.1 47.2 13.7
Male (%) 47.8 47.8 0.92* (0.98–1.02) 49.8 0.60* (0.80–1.46)
Diabetes in parents (%) 26.7 25.6 0.65* (0.73–1.21) 31.8 0.16* (0.90–1.82)
Age (years) 54.5  5.7 54.7  5.5 0.53† (0.42 to 0.82) 54.2  5.7 0.49† (0.58 to 1.22)
BMI (kg/m
2) 27.0  4.9 26.6  4.6 0.12† (0.11 to 0.91) 26.0  4.0 0.01† (1.70 to 0.22)
Waist (cm) 92.3  13.2 91.7  12.7 0.39† (2.04 to 0.78) 89.9  12.5 0.02† (4.48 to 0.35)
SBP (mmHg) 133.9  16.4 134.1  15.6 0.57‡ (1.18 to 2.12) 133.6  15.9 0.52‡ (1.60 to 3.18)
DBP (mmHg) 83.7  9.4 83.4  9.3 0.83‡ (1.07 to 0.87) 82.5  9.0 0.83‡ (2.06 to 0.79)
LDL-C (mM/l) 3.3  1.0 3.3  0.9 0.95‡ (0.10 to 0.09) 3.4  0.9 0.47‡ (0.09 to 0.21)
HDL-C (mM/l) 1.6  0.4 1.5  0.3 0.13‡ (0.06 to 0.008) 1.6  0.4 0.78‡ (0.04 to 0.06)
Triglycerides (mM/l) 1.3 (0.9) 1.3 (0.8) 0.59‡ (0.06 to 0.04) 1.2 (0.7) 0.21‡ (0.11 to 0.03)
Glucose (mM/l) 5.7  1.4 5.9  1.5 0.02‡ (0.04–0.38) 6.2  2.7 0.001‡ (0.37–0.87)
Insulin (pM/l) 40.8 (21.6) 40.8 (19.8) 0.86‡ (0.03–0.04) 40.2 (16.2) 0.005 ‡ (0.12 to 0.02)
HOMA-B (U/ml/mM/l) 79.4 (44.6) 74.3 (44.6) 0.13 to 0.03 P  0.004‡ 73.2 (40.9) 0.29 to 0.13 p  0.001‡
HOMA-IR (mM/l  U/ml) 1.7 (1.0) 1.7 (1.0) 0.12‡ (0.01 to 0.08) 1.7 (0.8) 0.90‡ (0.07 to 0.06)
Diabetes (%) 3.8 6.6 0.01# (1.16–3.59) 8.0 0.006# (1.36–5.64)
Incident diabetes (%)
IFG (%) 12.9 15.3 0.18# (0.90 to 1.72) 15.9 0.16# (0.88–2.20)
Incident IFG (%)
MS (%) 24.1 24.3 0.49# (0.83–1.48) 18.9 0.70# (0.58–1.44)
Data are means  SD or median (interquartile range) for not-normally distributed values. *P values calculated by a linear logistic regression analysis by evaluating
the association of gender or diabetes in parents with CT and TT genotypes; †P values calculated by a linear regression analysis by evaluating the association of age
orBMIorwaistcircumferencewithCTandTTgenotypes;‡Pvaluescalculatedbyamultipleregressionanalysisbyevaluatingtheassociationofeachofthevariables
marked (one model for each variable) with CT and TT genotypes after adjusting for age, sex, BMI, waist circumference, and familial diabetes; #P values calculated
by a multiple logistic regression analysis by evaluating the association of each of the variables marked (one model for each variable) with CT and TT genotypes after
adjusting for age, sex, BMI, waist circumference, and familial diabetes; §data available in 1,031 subjects. DBP, diastolic blood pressure; HDL-C, HDL cholesterol;
LDL-C, LDL cholesterol; SBP, systolic blood pressure.
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Table 1—Continued
At follow-up
CC CT P (95% CI) TT P (95% CI)
580 699 201
39.1 47.2 13.7
60.6  5.7 60.8  5.6 0.51† (0.41 to 0.83) 60.3  5.8 0.50† (0.59 to 1.22)
27.1  4.9 26.9  4.6 0.41 (0.72 to 0.29) 26.2  3.9 0.02† (1.65 to 0.17)
93.6  13.1 93.4  13.0 0.74† (1.63 to 1.15) 92.1  10.4 0.14† (3.56 to 0.52)
134.8  16.8 136.4  17.8 0.003‡ (0.18–3.66) 134.6  16.4 0.34‡ (1.30 to 3.78)
82.9  9.9 83.4  9.4 0.14‡ (0.25 to 1.73) 82.3  8.5 0.88‡ (1.56 to 1.34)
3.5  1.0 3.6  1.0 0.50‡ (0.07 to 0.15) 3.6  1.1 0.71‡ (0.13 to 0.19)
1.5  0.4 1.4  0.4 0.39‡ (0.06 to 0.02) 1.5  0.4 0.51‡ (0.08 to 0.04)
1.3 (0.9) 1.3 (0.8) 0.43‡ (0.03 to 0.07) 1.2 (0.8) 0.75‡ (0.08 to 0.06)
5.3  0.9 5.7  1.2 0.001‡ (0.30–0.54) 6.1  1.7 0.001‡ (0.60–0.96)
45.5 (38.8)§ 44.9 (34.3)§ 0.54‡ (0.11 to 0.06) 43.6 (31.1)§ 0.005‡ (0.30 to 0.06)
97.2 (85.4)§ 85.5 (74.6)§ 0.25 to 0.05 P  0.005‡ 75.4 (70.4)§ 0.50 to 0.20 P  0.001‡
1.7 (1.6)§ 1.8 (1.5)§ 0.12‡ (0.02 to 0.16) 1.9 (1.3)§ 0.20‡ (0.04 to 0.22)
4.5 7.0 0.03# (1.06–2.99) 10.5 0.001# (1.63–5.91)
1.6 1.7 0.75# (0.48–2.78) 3.0 0.15# (0.75–6.37)
11.2 18.0 0.001# (1.31–2.51) 25.4 0.001# (1.90–4.39)
5.7 10.7 0.001# (1.35–3.20) 16.9 0.001# (2.11–5.98)
27.9 31.5 0.04# (1.02–1.75) 33.3 0.003# (1.22–2.64)
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